Park, C.-W. et al. 2020. The safety evaluation of FM101, an A3 adenosine receptor modulator, in rat, for developing as therapeutics of glaucoma and hepatitis. EXCLI Journal. 19, (Feb. 2020), 187–200. DOI:https://doi.org/10.17179/excli2019-2058.